E014 Patient experience of switching to biosimilar Benepali

Ahmad, Nadia; Morsley, Klara; Allard, Andrew; Yein, Khin; Hall, Katie; Watson, E.; Price, Elizabeth; Collins, David; Ahmed, Azeem; Carty, Sara; Waller, Rosemary

doi:10.1093/rheumatology/kez110.013

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other studies, patients have reported suboptimal communication during a biosimilar transition, including wanting more notice, not being satisfied with the verbal or written information, or not having their concerns satisfactorily dealt with (5, 12). Our participants reported receiving enough notice before the transition occurred, but some also experienced a lack of information and resources.…”

Section: Discussionmentioning

confidence: 99%

“…The present study builds on the scarce existing research that has explored patients’ experiences ( 5 , 11 , 12 ). However, there are limitations that should be acknowledged when considering the findings.…”

Section: Discussionmentioning

confidence: 99%

“…Other reports have demonstrated that patients were generally satisfied with biosimilar treatment following the transition, and the transition reduced their concerns ( 8 , 9 ). Patients have also reported feeling pressured to change ( 10 ), felt the delivery device had poor quality ( 11 ), and experienced issues with the logistics of the transition, including wanting more notice, a better delivery process and additional staffing to be seen quicker ( 12 ). A comprehensive evaluation of the transitioning process is needed to provide guidance for future brand changes.…”

Section: Introductionmentioning

confidence: 99%

“…A comprehensive evaluation of the transitioning process is needed to provide guidance for future brand changes. These should explore other key aspects of the transition, including the availability of patient support and care supplies, and changes to administrative burdens (e.g., receiving authorization or prescriptions), which have been overlooked ( 5 , 8 , 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Gasteiger,

Lobo,

Stanley

et al. 2023

ACR Open Rheumatology

View full text Add to dashboard Cite

ObjectiveTransitions to biosimilars are common to reduce the cost burden of biologics. While brand changes can be daunting for patients, few studies have explored patients’ experiences with the transitioning process. This study examined rheumatology patients’ experiences with a mandatory nationwide brand change to an adalimumab biosimilar.MethodsPeople with rheumatic diseases involved in the adalimumab transition in Aotearoa New Zealand completed a nationwide online survey. Participants (n = 117, 48% with rheumatoid arthritis) reported their satisfaction with the biosimilar, logistics and supply, information and communication, and availability of support. They also reported what did and did not go well during the transition and provided recommendations for future transitions.ResultsThe mean [SD] satisfaction score with the transition was 6.2 [3.2] on a 0‐10 scale, with 10 indicating high satisfaction. Participants were the least satisfied with the support and information from patient support organizations, and training for the device during the transition. Participants were most satisfied with the biosimilar supply, support from pharmacists, and how early they were informed before the transition occurred. After the transition, participants were less satisfied with the device quality, patient support program, biosimilar safety and efficacy, and the provision of alcohol wipes and sharps bins (p < 0.05 for all). Satisfaction with training for the biosimilar device (B = .25, p = .036) predicted overall satisfaction. Participants appreciated less injection pain and the ease of the biosimilar device. The lack of alcohol wipes and loss of the bio‐originator support program were viewed negatively.ConclusionFuture biosimilar transitions should ensure the availability of alcohol wipes, sharps bins, and a comparable patient support program. Patient support organizations could be involved in providing information to patients about the change.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Gasteiger,

Lobo,

Stanley

et al. 2023

ACR Open Rheumatology

View full text Add to dashboard Cite

show abstract

“…Biosimilar discontinuation rates were variable between studies and disease areas ranging from 2.6% to 38.5% [32,35,36,39,42,44,45,. Switch-back rates (to the reference biologic) ranged from 0.5% to 16% [7, 32, 36, 41-44, 61, 63, 64, 67-73], while the rate of switching to an alternative drug ranged from 0.9% to 18.2% [32,35,37,39,41,42,45,50,54,55,57,61,62,64,[67][68][69][70]. Common reasons for discontinuation resulting in a switch included loss of response (LOR) [39, 44, 52-57, 59, 62, 63, 66, 69, 70], disease activity [41-43, 45, 50, 51, 65, 67-69, 72], and AEs [42-45, 51, 53-55, 57, 59-61, 63-65, 67, 69, 70, 73], all of which could be directly associated with additional treatment costs.…”

Section: Discussionmentioning

confidence: 99%

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Hillhouse¹,

Mathurin

Parison

et al. 2021

Adv Ther

View full text Add to dashboard Cite

Introduction To save costs to the healthcare system, forced non-medical switch (NMS) policies that cut drug coverage for originator biologics and fund only less expensive biosimilars are being implemented. However, costs related to the impact of NMS on healthcare resource utilization (HCRU) must also be considered. This study aims to summarize the evidence on the economic impact of an originator-to-biosimilar NMS. Methods A systematic literature review (SLR) was conducted. Publications reporting on HCRU or costs associated with originator-to-biosimilar NMS in the real-world setting were searched in MEDLINE and EMBASE from January 2008 to February 2020. In addition to hand searching the reference lists of relevant publications and SLRs, key conference websites, PubMed, and various government sites were also searched for the 2 years preceding the search (2018–2020). Results A total of 1845 citations were identified, of which 49 were retained for data extraction. Most studies reporting on the HCRU associated with NMS reported on post-NMS HCRU alone without a comparison pre-NMS. However, four studies described a difference in HCRU (i.e., investigations pre- vs post-switch or between non-switchers vs switchers), all of which reported a relative increase in HCRU, including laboratory testing, imaging, medical visits, and hospitalizations, amongst patients who underwent an originator-to-biosimilar NMS. Most studies reporting on the costs associated with NMS reported significant savings following NMS on the basis of drug costs alone. However, four studies specifically reporting on the difference of costs following originator-to-biosimilar NMS all demonstrated an increase in HCRU-related costs associated with NMS (increase in HCRU-related costs of 4–37% or 148–2234 2020 Canadian dollars). Conclusion Amongst the studies that reported on the difference in HCRU pre- vs post-switch or between non-switchers and switchers, all showed an increase in HCRU and related costs associated with NMS, suggesting that the expected overall savings due to less costly drug prices may be reduced as a result of an increase in HCRU and its associated costs post-switch. Nevertheless, more real-world studies that include NMS-related healthcare costs in addition to drug costs are needed. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01951-z.

show abstract

Etanercept

2019

Reactions Weekly

View full text Add to dashboard Cite

E014 Patient experience of switching to biosimilar Benepali

Cited by 4 publications

References 0 publications

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Etanercept

Contact Info

Product

Resources

About